Topical glycopyrronium tosylate in primary axillary hyperhidrosis: a profile of its use
Compliance with ethical standards
Funding: The preparation of this review was not
supported by any external funding.
Conflicts of interest: Y. N. Lamb is an employee of Adis International Ltd./Springer Nature, is responsible for the article content and declares no conflicts of interest.
information about this Adis Drug Review can be found here
Glycopyrronium tosylate (Qbrexza™) is available as single-use, pre-moistened cloths and has been approved in the USA for the topical treatment of primary axillary hyperhidrosis in adults and children ≥ 9 years of age. Glycopyrronium tosylate is effective in reducing patient-reported severity of disease and gravimetrically measured sweat production in this patient population; improvements have been shown to be maintained throughout long-term treatment (up to 48 weeks). Glycopyrronium tosylate is generally well tolerated, with most adverse events being mild to moderate in severity. Glycopyrronium tosylate thus provides a self-administered, non-invasive alternative to topical antiperspirant therapy and clinic-based treatments in adults with primary axillary hyperhidrosis, and is the only alternative to topical antiperspirants specifically approved in children and adolescents ≥ 9 years of age.
© Springer Nature Switzerland AG 2019